MetaCap

Elicio Therapeutics (ELTX) vs Mereo BioPharma Group (MREO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elicio Therapeutics (ELTX) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 82.8% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -96.1% for ELTX. Mereo BioPharma Group is the larger company by market cap ($41.5 million vs $41.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELTX-82.84%MREO-85.56%
+84%-6%-95%
Nov 21, 20251 yearNov 20, 2026
ELTX-96.46%MREO-87.06%
+152%+22%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELTX versus MREO key metrics
MetricELTXMREO
Share price$1.45$0.26
Market cap$41.05M$41.52M
1-day change-3.33%-5.45%
YTD return-81.78%-37.65%
1-year return-82.84%-85.56%
5-year return-96.13%-86.32%
EPS (TTM)$-1.81$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$500.00K
Net income (latest FY)$-39.57M$-41.88M
Operating margin—-8021.40%
Net margin—-8375.60%
52-week high$16.00$2.37
52-week low$1.25$0.20
Distance from 52-week high-90.94%-89.03%
Analyst consensusstrong_buynone
Avg. price target upside+842.76%+653.85%
Average volume324.71K1.24M
Shares outstanding28.31M159.70M
Employees3339
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Mereo BioPharma Group

MREO stock →

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

ELTX vs MREO FAQ

Which is bigger, Elicio Therapeutics or Mereo BioPharma Group?

Mereo BioPharma Group (MREO) is larger, with a market capitalization of $41.52M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, ELTX or MREO?

ELTX returned -82.84% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.

Are Elicio Therapeutics and Mereo BioPharma Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons